Skip to main content

Table 2 Methylation status of SOCS3 promoter fragments

From: Prediction of steroid resistance and steroid dependence in nephrotic syndrome children

SOCS3 promoter fragment Study Group MMb n (%) MUc n (%) UUd n (%) OR [95% CI] P-value
SOCS3_1 NS patients n = 124 3 (2%) 115 (93%) 6 (5%) NS vs. C: 2.8 [0.3–23.4] 0.3552
(− 1070/− 926 bp) a SR patients n = 53 0 (0%) 51 (96%) 2 (4%) SR vs.SS: 0.7 [0.1–3.7] 0.6351
  SS patients n = 71 3 (4%) 64 (90%) 4 (6%) SR vs.SD: 0.6 [0.1–4.3] 0.5824
  PSS patients n = 40 1 (2%) 37 (93%) 2 (5%) SR vs.PSS: 0.8 [0.1–5.5] 0.7736
  SD patients n = 31 2 (6,5%) 27 (87%) 2 (6,5%) SD vs.PSS: 1.3 [0.2–9.9] 0.793
  Controls n = 55 1 (2%) 53 (96%) 1 (2%) SS vs. C: 3.2 [0.4–29.7] 0.3015
SOCS3_2 NS patients n = 124 0 (0%) 84 (68%) 40 (32%) NS vs. C: 6.1 [2.1–18] 0.0011**
(− 256/− 285 bp) SR patients n = 53 0 (0%) 20 (38%) 33 (62%) SR vs.SS: 15.1 [5.8–39.3]  < 0.0001***
  SS patients n = 71 0 (0%) 64 (90%) 7 (10%) SR vs.SD: 15.4 [5.1–57.3]  < 0.0001***
  PSS patients n = 40 0 (0%) 36 (90%) 4 (10%) SR vs.PSS: 14.9 [4.6–48]  < 0.0001***
  SD patients n = 31 0 (0%) 28 (90.3%) 3 (9.7%) SD vs.PSS: 1 [0.2–4.7] 0.9639
  Controls n = 55 0 (0%) 51 (92.7%) 4 (7.3%) SS vs. C: 1.4 [0.4–5] 0.6113
  1. aRefers to ATG triplet; bMM refers to full methylation of the fragment; cMU refers to partial methylation of the fragment; dUU refers to full unmethylation of the fragment; significant results are shown in bold, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
  2. NS nephrotic syndrome; SR, steroid resistant; SS, steroid sensitive; SD, steroid dependent; PSS, primarily steroid sensitive